...
首页> 外文期刊>Clinical journal of the American Society of Nephrology: CJASN >Renal, ocular, and neuromuscular involvements in patients with CLDN19 mutations
【24h】

Renal, ocular, and neuromuscular involvements in patients with CLDN19 mutations

机译:CLDN19突变患者的肾,眼和神经肌肉受累

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background and objectives: The objective of this study was to describe the renal and extrarenal findings in patients with recessively inherited familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) associated with CLDN19 mutations. Design, setting, participants, & measurements: Medical records of three patients from two French unrelated families with CLDN19 mutations were retrospectively examined. Results: Direct sequencing of CLDN19 identified a known variant (p.Gly20Asp) in all patients and a new missense mutation (p.Val44Met) in one (compound heterozygous). The patients' renal phenotype closely mimicked CLDN16-related nephropathy: low serum Mg 2+ (0.65 mmol/L) despite oral supplementation, hypercalciuria partly thiazide-sensitive, and progressive renal decline with ESRD reached at age 16 and 22 years in two individuals. Primary characteristics (failure to thrive, recurrent urinary tract infections, or abdominal pain), age at onset (0.8 to 16 years), and rate of renal decline were highly heterogeneous. Ocular involvement was identified in all patients, although two patients did not have visual loss. Additionally, exercise intolerance with pain, weakness, and electromyographical alterations mimicking a Ca 2+/K + channelopathy (pattern V) were observed in two of three individuals. These features persisted despite the normalization of serum K + and Mg 2+ after renal transplantation. Conclusions: Ocular manifestations, even subtle, and exercise intolerance mimicking mild to moderate periodic paralysis are two symptoms that need to be searched for in patients with FHHNC and may indicate CLDN19 mutations.
机译:背景与目的:这项研究的目的是描述伴有CLDN19突变的隐性遗传性家族性低镁血症伴高钙尿和肾钙化病(FHHNC)的患者的肾脏和肾外表现。设计,设置,参与者和测量:回顾性检查了来自法国两个无关家庭的CLDN19突变的三名患者的病历。结果:CLDN19的直接测序在所有患者中鉴定出一个已知变体(p.Gly20Asp),在一个患者中(复合杂合子)鉴定了一个新的错义突变(p.Val44Met)。患者的肾脏表型与CLDN16相关的肾病密切相似:尽管口服,但血清Mg 2+低(<0.65 mmol / L),高钙尿症部分对噻嗪类敏感,并且在16岁和22岁时有2名患者的ESRD逐渐出现肾衰。主要特征(壮成长,尿路反复感染或腹痛),发病年龄(0.8至16岁)和肾衰率极不相同。在所有患者中都发现了眼部受累,尽管两名患者没有视力下降。此外,在三个人中的两个中,观察到运动不耐症,表现为疼痛,虚弱和模仿Ca 2 + / K +通道病的肌电图改变(模式V)。尽管肾移植后血清K +和Mg 2+正常化,这些特征仍然存在。结论:FHHNC患者需要寻找的两个症状,包括轻度到中度的周期性麻痹,甚至是微妙的运动不耐,都可能是CLDN19突变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号